Showing posts with label Not. Show all posts
Showing posts with label Not. Show all posts

Sunday, August 20, 2017

Cymbalta Not Only For Chemo Related Neuropathy


Today's post from drugs.com (see link below) talks about Cymbalta (antidepressant - duloxetine) being both approved and promoted for the relief of chemotherapy-induced neuropathic pain. It is already approved for other disease related neuropathies and is often seen as an alternative to Lyrica (anti-convulsant - pregabalin). As you know, there are many causes of neuropathy but the symptoms remain the same for the vast majority of people: the distinction between chemotherapy, diabetes, HIV, alcohol-related neuropathies is often emphasised when the symptoms are pretty much universal to them all. There are two other points to bear in mind here:
Pfizer, the manufacturers of Lyrica have withdrawn their own approval of Lyrica for diabetes and HIV-related neuropathy, (May 2012) due to its proven inefficiency and the high incidence of serious side effect issues and yet the drug is still widely prescribed for all forms of neuropathic pain!
Both Cymbalta and Lyrica have the potential for serious side effects, which affect considerable numbers of people. As far as the chemotherapy trial is concerned, if you regard a 59% success rate in the study as being conclusive, then fair enough but these drugs are prescribed for neuropathy despite being originally meant to treat other diseases. The theory is that they can influence pain receptors and sodium channels and thus reduce pain but just as with all other drugs used to treat neuropathic symptoms, what works for one doesn't work for the other. If your doctor prescribes either Cymbalta or Lyrica for you, it might be advisable to do your research before beginning and start a serious discussion with your doctor as to whether they are the best option for you. Armed with as many facts as possible, you will be able to make more reasoned choices. Remember also, that stopping either drug 'cold turkey' is not advisable; you will need to be weaned off gradually.


Antidepressant Lessens Chemo-Related Pain
TUESDAY April 2, 2013


 -- The antidepressant drug Cymbalta can help relieve chronic pain caused by certain cancer drugs, a new clinical trial reports.

The study, appearing in the April 3 issue of the Journal of the American Medical Association, tested Cymbalta on patients with chronic cases of chemotherapy-related peripheral neuropathy -- pain, tingling and numbness in the limbs that arises when certain chemo drugs damage the nerves.

Of 115 patients who took the antidepressant for five weeks, 59 percent got some degree of pain relief, compared with 38 percent of patients given a drug-free placebo.

Researchers said the findings support what some doctors have seen in everyday practice, since Cymbalta is already used to treat the chemo side effect.

That use has been based on the fact that Cymbalta helps with other types of pain, said Dr. Michael Stubblefield, who was not involved in the study but treats patients with chemo-induced peripheral neuropathy at Memorial Sloan-Kettering Cancer Center in New York City.

In the United States, the drug -- known chemically as duloxetine -- is approved to treat diabetes-related peripheral neuropathy, as well as fibromyalgia and chronic pain from arthritis.

Until now, cancer specialists have had to "steal" from evidence that Cymbalta helps with those forms of nerve pain, Stubblefield said.

"This is the first study of its kind to show that this works against chemotherapy-related neuropathic pain," he said.

It is estimated that 20 percent to 40 percent of patients treated with certain cancer drugs -- including so-called taxanes and platinums -- will develop peripheral neuropathy. For most, the problem improves once their chemo is over, said Ellen Lavoie Smith, the lead researcher on the study. But for some, she added, the nerve pain becomes chronic -- lasting for months or years after their chemo ends.

"This study focused on those patients," said Smith, an assistant professor of nursing at the University of Michigan School of Nursing, in Ann Arbor.

"The findings show that there is a medication that may be effective for reducing their pain from neuropathy," Smith said. But, she added, it didn't help everyone; the majority of Cymbalta patients improved, while others saw no change -- and 10 percent got worse.

The study included 231 patients with nerve pain that had persisted for at least three months since their chemo regimen ended. Half were randomly assigned to take Cymbalta for five weeks, while the other half took placebo pills. The two groups then switched treatments. None of the patients knew when they were taking the real drug and when they were on the placebo.

Of the patients given Cymbalta first, the average pain score fell by a point on a scale of 0 to 10. That's considered to be a "clinically important" change, Smith said, meaning it's an improvement patients notice in their daily lives.

The Cymbalta patients were also twice as likely to have a 50 percent decrease in pain scores versus the placebo users, and overall they reported improvements in their daily functioning and quality of life.

It is not clear how the antidepressant helps with nerve-related pain, but it is thought to act on certain brain chemicals involved in transmitting pain signals.

The findings are encouraging, Stubblefield said. But, like Smith, he pointed out that not everyone responds to Cymbalta. "This doesn't mean I'll be putting all my patients on it," he said.

There are other treatments for chemo-related pain -- although they have not yet been shown to work in rigorous clinical trials. One option, Stubblefield said, is Lyrica (pregabalin), which is another drug approved to treat other forms of nerve-damage-related pain.

Stubblefield said Lyrica tends to have fewer side effects than Cymbalta, and at least some patients may be able to tolerate it better. Cymbalta's side effects include fatigue, insomnia and nausea, which were reported by 5 percent to 7 percent of patients in the current study.

On the other hand, Stubblefield said, if a patient with nerve pain is also feeling depressed, it makes sense to try Cymbalta first.

There's also cost. Cymbalta is not yet available as a generic, and runs close to $200 a month. It is scheduled to lose patent protection at the end of 2013, so cheaper versions may become available.

Smith said there are still many questions to sort out: How well can patients tolerate Cymbalta over a longer term? Does the drug help nerve pain in patients who are still on chemo?

"We anticipate that it would help," Smith said. "But to what degree? Would it be enough to make a difference in their lives?"

As better treatments are helping more cancer patients survive, chronic peripheral neuropathy is emerging as one of the most difficult side effects of the treatments, said Dr. Sandra Swain, president of the American Society of Clinical Oncology.

Even minor actions, like picking up your keys, become difficult, Swain said. "It really affects your everyday living," she said.

Swain said the bottom line for patients is that "this drug may actually work, and it's something you can discuss with your doctor."

Still, Swain added, more research is needed -- not only into Cymbalta, but into other treatments for chemo-related pain.

Eli Lilly, the company that makes Cymbalta, provided the drug for the study. The work was funded by government and non-profit grants, and none of the researchers reported financial ties to Eli Lilly.

More information

Learn more about chemo-related neuropathy from the American Cancer Society.

http://www.drugs.com/news/antidepressant-lessens-chemo-related-pain-43944.html

Friday, August 11, 2017

Combining Drugs For Neuropathic Disease Treatment Why Not


Today's post from sciencedaily.com looks at a new treatment for fibromyalgia, which is a chronic and mysterious disease recently found to be linked to neuropathy by the fact that it is stimulated by the central nervous system (brain and spinal cord). It suggests that a combination of pregabalin (Lyrica) and duloxetine (Cymbalta) works very well at reducing the symptoms. The direct link to neuropathy is obvious as both drugs are used singularly to treat neuropathy symptoms. It has also been suggested in the past that combination therapies are the best options for severe neuropathic symptoms but many doctors are reluctant to go down that path because of side effects. The side effects should not be underestimated (especially pregabalin (Lyrica) which has such a bad name yet is still widely prescribed for many neuropathies but the idea of combining treatments is not a bad one and one worthy of consideration in discussion with your doctor or neurologist. Combinations excluding Lyrica may be best, to avoid unpleasant side-effects but surely other options can be considered - there are enough drug treatments to choose from and as they rarely work on their own, a combination which will block pain bearing signals in the sodium channels seems like a logical step forward.

Fibromyalgia: Doubling up to fight pain
Combining two drugs used to treat fibromyalgia safely improves patient outcomes, according to researcher 
Date:July 13, 2016 Source:Queen's University

Queen's University researcher Ian Gilron has uncovered a more effective way of treating fibromyalgia, a medical condition characterized by chronic widespread pain typically accompanied by fatigue, as well as sleep, mood and memory problems.

The results of the trial suggest that combining pregabalin, an anti-seizure drug, with duloxetine, an antidepressant, can safely improve outcomes in fibromyalgia, including not only pain relief, but also physical function and overall quality of life. Until now, these drugs have been proven, individually, to treat fibromyalgia pain.

"Previous evidence supports added benefits with some drug combinations in fibromyalgia," says, Dr. Gilron (Anesthesiology, Biomedical Sciences). "We are very excited to present the first evidence demonstrating superiority of a duloxetine-pregabalin combination over either drug alone."

Fibromyalgia was initially thought to be a musculoskeletal disorder. Research now suggests it's a disorder of the central nervous system -- the brain and spinal cord. Researchers believe that fibromyalgia amplifies painful sensations by affecting the level and activity of brain chemicals responsible for processing pain signals.

"The condition affects about 1.5 to 5 per cent of Canadians -- more than twice as many women as men. It can have a devastating on the lives of patients and their families," explains Dr. Gilron. "Current treatments for fibromyalgia are either ineffective or intolerable for many patients."

This study is the latest in a series of clinical trials -- funded by the Canadian Institutes of Health Research (CIHR) -- that Dr. Gilron and his colleagues have conducted on combination therapies for chronic pain conditions. By identifying and studying promising drug combinations, their research is showing how physicians can make the best use of current treatments available to patients.

"The value of such combination approaches is they typically involve drugs that have been extensively studied and are well known to health-care providers," says Dr. Gilron.

This new research was published in the journal Pain.

Dr. Gilron and his research team at Queen's are members of the SPOR Network on Chronic Pain. The national network, funded under Canada's Strategy for Patient-Oriented Research, directs new research, trains researchers and clinicians, increases access to care for chronic pain sufferers, and speeds up the translation of the most recent research into practice.



Story Source:

The above post is reprinted from materials provided by Queen's University. The original item was written by Anne Craig. Note: Materials may be edited for content and length.

Journal Reference:
Ian Gilron, Luis E. Chaparro, Dongsheng Tu, Ronald R. Holden, Roumen Milev, Tanveer Towheed, Deborah DuMerton-Shore, Sarah Walker. Combination of pregabalin with duloxetine for fibromyalgia. PAIN, 2016; 157 (7): 1532 DOI: 10.1097/j.pain.0000000000000558


https://www.sciencedaily.com/releases/2016/07/160713143152.htm

Sunday, July 2, 2017

VITAMIN D MAY NOT LOWER SENIORS FALL RISK



 Taking vitamin D supplements does little to reduce seniors’ risk of falls, a new review finds.
Researchers analyzed 20 studies that included nearly 30,000 people and tested how vitamin D supplements affected fall risk.
The results showed that the supplements did not reduce falls by 15 percent or more, which means they had little effect, according to Mark Bolland of the University of Auckland in New Zealand, and colleagues.
They concluded that there is insufficient evidence to support recommending vitamin D to seniors to lower their risk of falls, and also said that current ongoing studies investigating this theory are unlikely to change the conclusion.
The study was published in the April 23 issue of The Lancet Diabetes and Endocrinology journal.
The researchers noted that current evidence does not show whether taking vitamin D supplements might reduce falls in particularly vulnerable older people, such as those who fall often. This is because most studies examine only the total number of falls among all participants, rather than the number of falls per person.
Until now, some evidence that vitamin D supplements might prevent falls has led certain health organizations to recommend the use of the supplements, the review authors noted.
“Whether a large trial is feasible in this vulnerable population remains to be established. Until then, we are left with uncertainty about the benefits of vitamin D supplementation for reduction in fall risk, particularly among vulnerable older people,” Clifford Rosen, of the Maine Medical Research Institute, and Christine Taylor, of the U.S. National Institutes of Health, wrote in an accompanying commentary.






Thursday, May 25, 2017

MRI Scan Can Prove Whether Chronic Pain Drugs Work Or Not


Today's post from sciencedaily.com (see link below) looks at the possibility of using an MRI scan to measure the effectiveness of new drugs meant to reduce chronic pain. The MRI measures the nerve cells in the brain's response to pain signals and can see very quickly if they respond positively. Apparently one of the problems with new drugs is that it takes so long to prove effectiveness or not. By using a non-invasive MRI scan, gathering that evidence (from the behaviour of the brain's neurological response,) will be both quicker and more accurate, thus reducing the amount of time patients have to wait for proven new drugs for chronic pain.

Functional MRI may help identify new, effective painkillers for chronic pain sufferers 
Date:February 4, 2016 Source:American Society of Anesthesiologists

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists (ASA), using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development -- providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies.

"Many potential pain relieving drugs identified in preclinical research fail to reach the market because of a lack of early objective evidence that shows whether a drug is effectively reaching target pain receptors in the body and regulating chronic pain mechanisms," said Vishvarani Wanigasekera, M.D., study lead author and clinical post-doctoral research fellow, Nuffield Division of Anaesthetics, University of Oxford, England. "We have used noninvasive FMRI to successfully obtain such evidence that we hope can help to prevent the premature discarding of potentially effective pain relievers, as well as avoid exposing patients to ineffective ones."

Currently, patient reported pain relief is the primary outcome measure used in human drug development studies to assess whether a pain relieving medication is effective. However, due to their subjective and context-dependent nature, self-reported pain perception and relief is subject to many influences, in addition to the actual pain relieving effectiveness of the drug. Early drug development studies typically involve a small sample size. When subjective pain reports are used as the sole outcome measure in these studies, researchers can easily miss effective compounds that might work well in the population at large.

In the double-blind, randomized study, researchers induced a phenomenon called central sensitization and some symptom-like features of neuropathic pain, a complex chronic pain condition, on three separate occasions in 24 healthy volunteers by applying capsaicin cream, a topical irritant often used to produce similar characteristics of neuropathic pain in an experimental setting, on the subjects' skin. Prior to capsaicin cream application, subjects either received a single dose of gabapentin, which is considered effective and a first line treatment for neuropathic pain; ibuprofen, which is generally not considered an effective treatment for the condition; or a placebo. Researchers then assessed the effect the drugs or placebo had on the brain's neural response to pain using FMRI in addition to patient reported pain relief.

They found in the absence of behavioral measures distinguishing which drug was most effective at low subject numbers, the imaging responses were clear. Pain relevant neural activity was significantly reduced in the subjects who received gabapentin, even with extremely low subject numbers, highlighting the potential for FMRI to make a drug's effect clear in small cohorts.

The authors acknowledge that the mechanisms and neural activity involved in the expression of pain in neuropathic patients is not exactly the same as in the healthy subjects with capsaicin cream-induced pain. However, similar studies in early human drug development can determine whether a drug has the ability to affect relevant neural activity in the brain.

"There is a clear need for more effective, safer pain relievers," said Dr. Wanigasekera. "Chronic pain is a very common condition. Even the most effective pain medications currently available only provide adequate pain relief, defined as a 50 percent reduction in pain, in one out of four patients, while some drugs, such as opioids, have significant side effects, including dependence and overuse. We believe that neuroimaging techniques, such as FMRI, can provide objective evidence that can be used as outcome measures in early drug development to enhance the efficiency of the drug development process."

Story Source:

The above post is reprinted from materials provided by American Society of Anesthesiologists. Note: Materials may be edited for content and length.

Journal Reference:

Vishvarani Wanigasekera, Melvin Mezue, Jesper Andersson, Yazhuo Kong, Irene Tracey. Disambiguating Pharmacodynamic Efficacy from Behavior with Neuroimaging. Anesthesiology, 2016; 124 (1): 159 DOI: 10.1097/ALN.0000000000000924


http://www.sciencedaily.com/releases/2016/02/160204121949.htm

Thursday, May 4, 2017

Burning And Tingling Not The Only Symptoms Of Neuropathy


Today's post from dailyalternativehealthandwellness.com (see link below) is a correction of the common misconception that pain, numbness and tingling in the feet are the only symptoms of neuropathy and nerve damage. They're not and as the article points out, if motor nerves are damaged, then a whole raft of other symptoms can be the result. It is true that the commonest symptoms of neuropathy are to be found in the feet but there are over 100 forms of neuropathy with also more than 100 different possible causes. It's possible you may feel some symptoms but not others and/or a combination of all of them. It's a disease you can't fit neatly into fixed rules and regulations and this article is quite right in pointing that out.

Neuropathy And Loss Of Muscle Control Symptoms
March 5, 2016 by admin

Have you noticed your muscles acting a little strange since developing neuropathy? Perhaps they affect your ability to walk? Or maybe you find it difficult to use your fingers to pick something up? While we normally associated peripheral neuropathy with symptoms like pain, numbness and tingling – there are other symptoms as well.

It is a known fact that the peripheral nervous system is made up of three different kinds of nerves: motor, sensory and autonomic. In addition, each type of nerve controls different functions. Motor nerves send signals from the brain and spinal cord to your muscles – controlling motor functions like walking, dexterity and more. Sensory nerves do the opposite – relaying signals like temperature, pain, etc. from the muscles back to the brain and spinal cord. Finally, the autonomic nerves control involuntary or semi-voluntary functions like heart rate, digestion, blood pressure and more.

Peripheral neuropathy can affect some or all of these nerves. The symptoms you experience will depend entirely upon the type of nerve(s) that have been damaged as a result of your neuropathy. If your sensory nerves have been damaged you will experience symptoms such as pain, numbness, tingling or burning. Damage to the autonomic nerves can lead to problems with dizziness, sweating (either too much or too little), nausea, vomiting, diarrhea, constipation, difficulty urinating and more.

If your motor nerves fall victim to nerve damage – various motor functions can be affected. Let us take a look at five possible symptoms you might experience if your neuropathy has damaged your motor nerves:
Loss of balance and difficulty walking – Damage to the motor nerves can make walking difficulty.

Loss of Dexterity – A few common difficulties associated with loss of dexterity are inability to grip objects, loss of hand strength, difficulty writing or typing, difficulty performing tasks that require small movements, decreased reflexes and more.

Muscle Weakness & Deterioration – For many, decrease in physical activity results in muscle deterioration and weakness. As the muscles deteriorate, you lose muscle mass and tone.
Cramps & Spasms – Generally, the cramping strikes at night and can range in severity from mild to extremely painful.

Loss of Muscle Control – Generally, you will have loss of reflexes, inability to move hands or feet quickly, difficulty with fine motor tasks (i.e. buttoning a shirt, writing, etc) and more.

Just remember, while the most common symptoms associated with peripheral neuropathy are pain, numbness, burning or tingling in the hands or feet – they are not the only symptoms.

http://dailyalternativehealthandwellness.com/neuropathy-and-lost-of-muscle-control-symptoms/